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Abstract
Background: Treatment strategies for T3 laryngeal carcinoma include radiotherapy (RT) with or without chemotherapy
(CT) and sometimes surgery. We conducted a national survey to determine how T3 laryngeal carcinoma is currently
being managed in the Netherlands.
Methods: A questionnaire on general treatment policy, also inquiring details on RT and CT, was sent to all 13
radiotherapy departments accredited for treatment of head and neck cancer (HNC) in the Netherlands.
Results: Twelve centers completed the questionnaire. All centers reported using RT with or without CT. Upfront
laryngectomy is rarely performed.
At 9/12 centers, CT is added to RT in cases with large tumors in T3N0 disease. Three centers use a volume criterion
(3–6 cc); 6 centers don’t specify “large” with such criteria. CT consists of cisplatin 3-weekly (7 centers) or weekly
(2 centers), unless contra-indicated or age; 6 centers use an age limit of 70 years. RT is given concomitantly with
CT 5×/week except at the 2 centers where cisplatin weekly is combined with 6 fractions/week. In case of RT
only, treatment is accelerated. Lymph node levels II-IV are treated electively.
In T3N+ disease, 11/12 centers treat non-bulky T3N1 with RT only. Volume criteria for combined CT-RT are the
same as above. Two centers perform an upfront neck dissection in case of (resectable) N3 disease; 10 centers
treat T3N2-3 cancer with primary CT-RT, 2 centers don’t use the N-stage criterion.
Total RT dose is 68–70 Gy, the elective dose varies between 46 and 57.75 Gy. Eight centers use a simultaneous
integrated boost technique.
Conclusions: Treatment of T3 laryngeal cancer in the Netherlands is generally comparable, with CT-RT for voluminous
T3N0 and most T3N+ tumors, but there are some differences between the centers in the use of chemotherapy and the
dose-fractionation schemes. Therefore, the aim of the National Platform RT HNC is further standardization of RT dose,
fractionation and delivery techniques.
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Background
Laryngeal cancer is relatively rare, with an estimated in-
cidence of 12,630 new cases in 2014 out of a total num-
ber of 1,665,540 new cancer cases in the United States
[1]. In the Netherlands, the yearly incidence of laryngeal
carcinoma is approximately 700 patients out of a total
of around 100,000 new cases of cancer [http://www.
cijfersoverkanker.nl/selecties/Incidentie_long_en_luchtpijp-
kanker/img556836474c735].
Almost all laryngeal malignancies occur in the glottis
(2/3) and supraglottis (1/3), with subglottic tumors ac-
counting for only 2 % [2]. More than 80 % of glottic tumors
are diagnosed at an early stage, whereas in supraglottic can-
cer this is around 30 % [3]. These tumors are treated with
single modality therapy, i.e. RT or transoral (laser) surgery,
with 5-year survival rates above 85 % for stage I and around
75 % for stage II [4, 5].
In the 1990s, after the Veterans Affairs laryngeal pres-
ervation study showed comparable survival outcomes
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between total laryngectomy and induction CT followed
by RT [6], treatment of stage III–IV locoregionally ad-
vanced laryngeal cancer shifted away from surgery towards
primary organ preservation strategies. A large retrospective
survey on treatment of T3 larynx cancer in the Netherlands
demonstrated an inferior outcome with split course RT
compared to definitive RT, upfront surgery or RT followed
by surgery, leading to abandonment of the split course
RT strategy [7]. A decade later, RTOG 91–11 showed
concurrent chemoradiotherapy (CT-RT) to be superior
to induction CT followed by conventionally fractionated
RT or conventionally fractionated RT alone for locoregio-
nal control (78 % versus 61 and 56 %, respectively at
2 years) in stage III–IV laryngeal cancer [8]. Around the
same time, studies with accelerated radiotherapy (AR) also
reported local control rates of up to 80 % [9–12].
Early stage larynx cancer is treated with radiotherapy
alone, whereas for T4 tumors total laryngectomy or che-
moradiotherapy is the treatment of choice. In T3 laryngeal
cancer however, guidelines are less clear. National com-
prehensive cancer network (NCCN) guidelines advocate
CT-RT, single modality RT (in patients unfit for or refus-
ing chemotherapy), laryngectomy (if organ preservation is
deemed impossible) or induction CT followed by RT with
or without concomitant CT (preferably within a trial)
[NCCN guidelines 2–2014]. The 2010 Dutch guidelines
recommend organ sparing treatment (if possible) by using
concomitant CT-RT or accelerated RT; no volume thresh-
old is stated [http://www.oncoline.nl/index.php?pagina=/
richtlijn/item/pagina.php&richtlijn_id=666].
A uniform approach to the treatment of T3 laryngeal
cancer would be desirable in order to achieve the best
outcome in terms of tumor control and toxicity. How-
ever, the relatively low incidence, combined with the fact
that (1) these patients are managed in multiple centers
and (2) several treatment options are used in the current
national guidelines could hamper this uniformity. We there-
fore conducted a survey to identify how T3 laryngeal
carcinoma is currently being managed in the Netherlands.
For more than 2.5 decades, treatment of HNC in the
Netherlands has been centralized and restricted to the
centers of the Dutch Head and Neck Oncology Coopera-
tive Group (DHNOCG, Nederlandse Werkgroep Hoofd-
Halstumoren) and their affiliated centers. A questionnaire
was sent to the radiotherapy departments of the 8 centers
that together make up the DHNOCG and the 5 preferred
partner centers. These latter centers have committed
themselves to use the same treatment protocols as the
related DHNOCG center.
Methods
The centers of the DHNOCG and the preferred partners
were invited to participate in the survey. In addition to
asking about the general approach to treatment, we also
collected detailed information about the practice of RT
and CT-RT at the various centers.
The questions were emailed to the radiation oncologists
of these 13 centers who also are the members of the
National Platform RT HNC (Landelijk Platform Radio-
therapie Hoofdhals Tumoren), an assembly of radiation
oncologists representing the 8 DHNOCG centers and
their affiliated centers.
The survey included the following questions:
– How is a T3N0 laryngeal carcinoma treated at your
center?
– How is a T3N+ laryngeal carcinoma treated at your
center?
– Is there a difference in treatment between a
supraglottic and glottic tumor?
– Which elective lymph node levels are treated?
– Does tumor volume play a role in your treatment
selection?
– Does nodal stage or volume play a role in your
treatment selection?
– What is your preferred choice of chemotherapy or
biological therapy and do you have an upper age
limit for these therapies?
An additional questionnaire was included with specific
questions on the radiotherapy treatment; these questions
are listed on Table 1.
Table 1 Questionnaire on radiotherapy treatment
Preparation
Do you perform an MRI in a mask?
Is your diagnostic MRI matched with the planning CT for delineation?
Do you obtain a PET-CT in mask?
Is your diagnostic PET-CT matched with the planning CT for delineation?
Delineation-Margins
What is your gross tumor volume (GTV)-clinical target volume (CTV)
margin (boost volume)?
What is your GTV-CTV margin (elective volume)?
What is your planning target volume (PTV) margin (boost volume)?
What is your PTV margin (elective volume)?
Dose- Technique
What is your total boost dose?
What is the fraction size for the boost dose?
What is your total elective dose?
What is the fraction size for the elective dose?
Do you use a simultaneous integrated boost (SIB) or sequential
boost (SEQ?
Do you use static intensity modulated radiotherapy (IMRT) or
volumetric modulated arc therapy (VMAT)?
What is your protocol for position verification and correction during
treatment?
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The results were collected in the spring of 2014, with
an update and additional questions in December 2014
and a final update in May 2015.
Results
All 8 DHNOCG centers and 4 preferred partners com-
pleted the questionnaire. The responses are summarized
below.
T3N0 larynx carcinoma
All centers use primary RT, with or without concurrent
CT. Five centers report the option of upfront total lar-
yngectomy in exceptional cases (i.e. stridor or a non-
functional larynx). At 9 centers the decision to combine
RT with CT is based on tumor volume; 3 centers did
not report a primary tumor volume criterion.
T3N+ larynx carcinoma
Except for “non-bulky” T3N1 laryngeal tumors, almost all
T3N+ cancers at the centers are treated with concomitant
chemoradiotherapy. Two centers do not use an N-stage
criterion.
Two centers reported that patients presenting with a
non-fixed N3 lymph node undergo an upfront neck dis-
section, followed by CTRT for the primary tumor and
elective neck dissection. Two other centers recently aban-
doned the strategy of upfront neck dissection.
Chemotherapy indication and regimens
The indications for combining chemotherapy with radio-
therapy were reported as follows:
 volume of the primary tumor: cut-off volume of
3.5 cc (2 centers) or 6 cc (1center) for glottic tumors,
cut-off volume of 6 cc for supraglottic tumors:
3 centers, “bulky” tumor: 6 centers
 nodal stage: N1: 1 center, N2a: 10 centers, N2b: 9
centers, N3: 10 centers (of which 2 centers sometimes
perform an upfront neck dissection)
 suspicion of extranodal spread on imaging: 4 centers
 submucosal spread: 1 center
 subglottic extension: 1 center
The final decision to give chemotherapy is almost al-
ways based on a combination of these factors.
Ten centers reported that their treatment regimen of
choice is cisplatin 100 mg/m2 3 weekly and 2 centers re-
ported 40 mg/m2 weekly. Once center uses cisplatin for
T3N0, but carboplatin-5FU in case of T3N+ carcinoma.
If patients are deemed unfit to tolerate the 3-week regi-
men, cisplatin 40 mg/m2 weekly (3 centers) or 6 mg/m2
daily (1 center) is given. In case of a contra-indication to
cisplatin treatment (e.g. impaired renal function, vascular
morbidity) or a World Health Organization (WHO)
performance score >1, cetuximab is considered by 6
centers.
Above the age of 70 years, 3 centers reported that they
usually combine radiotherapy with cetuximab when the
patient is very fit. The other centers did not report com-
bined therapy for this age group.
Elective lymph node level treatment
For both glottic and supraglottic tumors, all centers treat
bilateral lymph node levels II–IV electively. For subglot-
tic tumors or subglottic extension, level VI is included.
In case of nodal involvement, level V is included. When
level IVa is affected, level IVb is included. All centers use
the consensus guidelines published by Gregoire et al. [13].
Radiation treatment preparation
For T3N0 laryngeal cancer, 1 center uses CT scanning for
diagnostic workup; at 11 centers a diagnostic MRI scan is
made. This MRI scan is fused with the planning CT scan
for contouring purposes. In 3 centers, the diagnostic MRI
scan is made in treatment position (i.e. in the treatment
mask): in 2 centers routinely, in 1 center only for selected
cases. In 1 other center, a second MRI scan is performed
in treatment position. In 2 centers, a PET-CT in treat-
ment position is made for both diagnostic and contour-
ing purposes.
For T3N+ laryngeal cancer, all centers use (diagnostic)
MRI scans for contouring. Seven centers perform a
PET-CT scan in treatment position, which is then used
for both diagnostic and delineation purposes.
Margins
The margin from the GTV to the CTVboost is 5 mm (8
centers), 6 mm (1 center) or 10 mm (2 centers). One
center reported a margin of 10 mm for the primary tumor
and 5 mm for the involved lymph nodes. To construct
an elective margin around the GTV, 5 mm (2 centers),
10 mm (8 centers) and 15 mm (2 centers) were reported.
Margins from CTV to PTV are 3 mm (2 centers), 4 mm
(2 centers) and 5 mm (8 centers). Some centers use an
additional margin in cranio-caudal direction for laryngeal
movement.
Fractionation, dose and technique
When RT alone is used, all 12 centers reported accelerated
treatment. At 6 centers an upper age limit of 70 years for
AR was reported. Ten centers use 6 fractions per week
(i.e. DAHANCA scheme); 2 centers apply an ‘accelerated
scheme only’ (ASO-scheme: weeks 1–2: 2 Gy/day on
boost and elective volume, 5 days/week (total 20 Gy),
week 3–5: 1.5 Gy on boost volume, 5×/week (morning)
and 1.8 Gy on boost and elective volume, 5×/week
(afternoon) (total 69.5 Gy on boost volume, 47 Gy on
elective volume) [10]. When combined with chemotherapy,
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10 centers stated that radiotherapy is conventionally
fractionated (i.e. 1 fraction/day), while 2 centers combine
weekly cisplatin with 6 fractions/week (i.e. DAHANCA
scheme).
All centers use a 2-level dose prescription (i.e. for
PTVboost and PTVelective), without intermediate dose.
Fractionation schemes are somewhat diverse (Table 2).
Dose prescription is set to 95 % of the dose covering at
least 95 % of the boost PTV at 2 centers, 98 % at 8 cen-
ters and 99 % at 2 centers, while keeping the volume
receiving >107 % as small as possible.
Eight centers reported that they always use a pure sim-
ultaneous integrated boost (SIB); 6 of these centers have
a single scheme, while the 2 remaining centers use 2
different schemes, depending on whether or not chemo-
therapy is added. The total boost dose varies between 68
and 70 Gy (2 Gy fraction dose); the total elective dose var-
ies between 50.3 and 57.75 Gy with fraction doses varying
between 1.48 and 1.65 Gy.
In case of radiotherapy only, 2 centers use the ASO
scheme, which is a combination of a sequential and an
integrated approach [10]. When concomitant CT-RT is
given, these centers use a SIB or sequential scheme. The
2 remaining centers mostly use a sequential scheme,
with a fraction dose of 2 Gy and a total dose of 46 Gy
to the PTVelective and 70 Gy to the PTVboost. Sometimes
a SIB scheme is given, i.e. in cases of N+ disease near
the parotid glands. The PTVboost then receives 70 Gy
(2 Gy/fraction), the PTVelective 54.25 Gy (1.55 Gy/fraction).
Six centers use VMAT, the 6 other centers use static
IMRT.
Set-up protocol and position verification (Image Guided
Radiotherapy (IGRT))
Three centers perform daily kilovoltage (kV) planar imaging
with online corrections. Additional cone beam CTs (CBCTs)
are used to monitor anatomical/soft tissue changes: at 1 cen-
ter, weekly CBCT scans are made, 1 center makes CBCT
scans in the first and fourth week (or weekly if volume
changes are anticipated); the remaining center performs
CBCT scans only in case of large clinical changes.
Seven centers use only CBCT scans (with offline review)
for set-up. Five centers use a no action level (NAL) proto-
col with a scan made on days 1–3 and a control scan (after
the resulting shift has been carried out) on day 4, and
thereafter weekly CBCT scans (and correction and a new
NAL series if necessary). One center performs 3 CBCT
scans in the first week and weekly scans in the following
weeks. One center uses daily CBCT set-up with an offline
correction protocol.
Two centers use megavoltage (MV) planar imaging with
a NAL correction protocol and perform CBCT scans
on indication (i.e. when relevant anatomical changes are
expected).
Discussion
The results of this survey, investigating current practice
in the Netherlands for T3 laryngeal cancer, show that
the majority of centers take a rather similar general ap-
proach to T3N0 and T3N+ disease, but the details of the
RT or CT-RT approaches differ. All centers use primary
radiotherapy for the primary tumor, with or without con-
comitant chemotherapy/biological therapy, and with or
without upfront neck dissection when deemed necessary.
Upfront total laryngectomy is performed rarely.
In T3N0 cancer, 9/12 centers use volume criteria to
choose between RT alone or concomitant CT-RT. Three
centers specify a volume, 6 centers use “bulky” as a cri-
terion and 3 centers don’t use a primary tumor volume
criterion. The impact of laryngeal tumor volume on tumor
control after RT alone has been investigated in several
studies [14, 15]. Cut-off values of 3.5 and 6 cc were re-
ported for glottic and supraglottic cancer respectively
[16, 17]. However, Van Bockel et al. also found signifi-
cant associations with outcome using tumor volume as
a continuous variable [15]. In their analysis, tumor vol-
ume was a better predictor for disease free survival than
T-stage, leading to their suggestion to incorporate tumor
volume in T-staging, as it is done in oro- and hypopharyn-
geal cancer. This was not confirmed by Janssens et al.; in
the large Dutch phase III ARCON trial, neither primary
tumor volume, nor total nodal volume was a prognostic
factor [18]. Interestingly, the 3 centers that did not report
a primary tumor volume criterion also took part in the
ARCON trial. However, it is still not convincingly clear if
cut-off volumes should be used, and if so, which ones.
The main justification for combining chemotherapy with
radiotherapy is to increase local control, hopefully leading
to a higher rate of larynx preservation. In the RTOG
91–11 study, at a follow up of 3.8 years, the larynx preser-
vation rate was significantly higher in the concomitant
CT-RT arm than the induction CT arm and RT alone arm
(84 % versus 72 and 67 %) [8]. A recent retrospective
series by Al Mamgani et al. showed significantly improved
local control (89.6 % versus 68 %) and laryngectomy-free
survival (76.8 % versus 53.5 %) at 3 years in favor of
CT-RT versus RT alone for T3 larynx cancer, with both
groups receiving 6 fractions a week [19]. Conversely,
Table 2 Fractionation schemes
SIB SIB SIB SIB SIB ASO SEQ
Boost dose: fraction 2 2 2 2 2 1.5/1.8/2 2
Boost dose: total 68 68 68 70 70 69.5 70
Elective dose: fraction 1.48 1.5 1.55 1.55 1.65 1.8/2 2
Elective dose: total 50.3 51 52.7 54.25 57.75 47.5 46
SIB simultaneous integrated boost scheme, ASO accelerated scheme only, SEQ
sequential scheme
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several groups have also reported favorable local control
with altered fractionation radiotherapy alone, although
these studies were not limited to (T3) larynx cancer.
DAHANCA 6 and 7 had 70 % overall 5-year locoregional
control with AR [9]. Terhaard et al. reported a 3-year local
control rate of 78 % for locally advanced laryngeal cancer
treated with the ASO scheme [10]. A phase II study com-
bining AR with carbogen and nicotinamide (ARCON) in
215 HNC patients showed an actuarial 3-year local con-
trol rate of 80 % for T2-4 larynx cancer [11]. A subsequent
phase III trial in 345 patients resulted in a local tumor
control rate at 5 years of 78 % for AR versus 79 % for
ARCON, with larynx preservation rates of 84 and 87 %,
respectively [12]. Notably, in this large trial no differences
in local control between T-stages were seen.
Because patients were enrolled in RTOG 91–11 be-
tween 1992 and 2000, staging was done according to the
4th and 5th edition of the American Joint Commission on
Cancer. However, paraglottic space invasion and minor
thyroid cartilage erosion were added to the staging system
only in the 6th edition (2003–2009). At that time, some
cases that are currently staged as T3 laryngeal carcinomas
would have been classified as a T2 tumor and treated
accordingly. The superiority of concomitant CT-RT treat-
ment, as a conclusion of the RTOG 91–11 study, may
therefore not apply to all T3 laryngeal carcinomas. This is
reflected in the Dutch guidelines, suggesting either pri-
mary radiotherapy or CT-RT for T3 laryngeal carcinomas
[http://www.oncoline.nl/index.php?pagina=/richtlijn/item/
pagina.php&richtlijn_id=666].
In the present survey, for T3N+ laryngeal cancer, nodal
stage is considered more important than primary tumor
volume for the addition of chemotherapy. One center
reported using CT-RT in all cases. With N2-3 disease,
almost all centers combine RT with CT. This is consist-
ent with Vergeer et al., who showed worse regional con-
trol in patients with a nodal volume of >14 cc treated
with RT alone versus CT-RT [20]. However, the 2 lead-
ing centers in the ARCON trial do not use a nodal vol-
ume criterion, which is in line with the results of their
study [18].
In RTOG 91–11 there was no survival benefit from
combined CT-RT. Also, a recent update failed to show
an overall survival difference between any of the 3 treat-
ment arms, although there was a trend for less distant
metastases in the combined arms [21]. This is probably
attributable in part to the possibility of a successful sal-
vage total laryngectomy in case of recurrent disease.
Nevertheless, a sub-analysis of the MACH-NC database
in laryngeal cancer patients from trials performed before
2000 showed a 4.5 % absolute survival benefit in favor of
CT-RT versus RT alone [22].
The downside of combining CT with RT is increased
toxicity. In RTOG 91–11, the rate of (acute and late)
high-grade toxicity was 82 % for the concomitant CT-
RT group versus 61 % for the radiotherapy alone group
[8]. In the recently published TREMPLIN trial, comparing
CT-RT to cetuximab + RT after induction chemotherapy
for larynx preservation, acute toxicity was substantial and
dose limiting, with only 42 % of patients in the CT-RT
arm receiving all 3 cycles of chemotherapy [23].
In this survey, the most important argument raised by
the centers in favor of chemotherapy in less advanced
cases is that the expected reduced risk of recurrent dis-
ease outweighs the toxicity of a combined treatment.
Centers that are more reluctant to use chemotherapy
(i.e. centers that took part in the ARCON study and
their affiliated centers), argue that 5-year local control
rates in this large study were high, also in the accelerated-
only arm, and that neither tumor volume nor nodal vol-
ume was a prognostic factor [12, 18].
Considering the RT schemes, there are minor varia-
tions in total boost dose, varying between 68 and 70 Gy.
The 2 centers in the present study that reported using
68 Gy were also the leading centers in the ARCON
trial, in which the boost dose was set to 68 Gy (in the
accelerated-only arm). The dose to the elective volume
differs more, with a total dose between 50.3 and 57.75 Gy
in the SIB schemes, a dose of 46 Gy in the sequential
scheme, and a dose of 47.5 Gy in the ASO scheme. The
reason for a higher dose in the SIB schemes is that the
total treatment time of the elective PTV is prolonged from
4–5 weeks (in the sequential and ASO scheme) to 6–7
weeks. Although no reliable data are available on the effect
of prolonging overall treatment time on control (or loss of
control) in elective nodal regions, it is believed it should
be compensated for. Since no robust data exist, the elect-
ive doses or fractions vary between the centers. Despite
these differences, reported Dutch regional outcomes are
good to excellent [10–12, 19].
Accurate and precise contouring of the tumor using
MRI in treatment position could possibly lead to smaller
CTV margins. All centers reported performing a diagnos-
tic MRI for T3N+ larynx cancer, but this scan is made in
treatment position at only 4 centers. Although not yet in
practice at all centers, most centers in the Netherlands are
working on MRI and PET-CT imaging in the treatment
mask.
There are some differences in IGRT practice. Centers
with Varian equipment (Palo Alto, Ca, USA) perform daily
online kV imaging, combined with periodical CBCT im-
aging, while users of Elekta (Stockholm, Sweden) primarily
do CBCT imaging with offline correction protocols. At all
but 4 centers, both approaches are combined with PTV
margins of no less than 5 mm, although Van Asselen et al.
showed that the mean parotid dose increased with in-
creasing margin by approximately 1.3 Gy per mm [24].
Co-registration of MRI imaging in treatment position,
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combined with well considered set-up protocols, could
possibly lead to smaller treatment volumes.
With the increased use of non-surgical treatment for
larynx cancer, it is relevant to look at trends in survival.
Chen et al. retrospectively reviewed more than 19,000
patients treated between 1996 and 2002 for advanced
stage laryngeal cancer and found that treatment with a
non-surgical procedure was associated with a higher risk
of death. This risk was reduced when treatment was per-
formed at a high-volume center, in which case survival
was better compared to a low-volume center [25]. A re-
cent report based on 21 RTOG trials showed the same,
with better overall survival in high-accruing centers [26].
This indicates the need for centralization of treatment of
low-incidence/high-impact cancer like T3 laryngeal car-
cinoma. In the Netherlands, this is well organized through
the Dutch Head and Neck Oncology Cooperative Group,
established 30 years ago to improve knowledge and cooper-
ation, and to centralize treatment of head and neck cancer
in the Netherlands. Nevertheless, despite centralization of
treatment, some differences between the centers continue
to exist in interpreting and implementing the guidelines
and the available literature, which is sometimes conflicting.
Therefore the current aim of the National Platform RT
HNC is to standardize the RT dose and fractionation. The
results of this survey have been discussed in the platform
and this has already led to some local practice changes.
Certain technical issues will also be harmonized, such as
planning and imaging protocols. In the future, we hope to
collect and analyze outcome data of treatment of larynx
cancer in the Netherlands; these results could help to
further harmonize treatment protocols.
Conclusions
As reflected by this survey, treatment strategies of T3 la-
ryngeal cancer in the Netherlands are rather comparable
between the 8 DHNOCG centers and their affiliated lo-
cations, but differences exist, especially when it comes
to the addition of concomitant chemotherapy. Radio-
therapy alone is reserved for small volume T3N0 and
T3N1 tumors, but not all centers use CTRT for higher
N-stages. Since there are also some discrepancies in the
details of the RT treatment between centers, the aim of
the National Platform RT HNC is to is further standardize
the RT dose, fractionation and delivery techniques.
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